Morpholino oligomer -: Mediated Exon skipping averts the onset of dystrophic pathology in the mdx mouse

被引:119
|
作者
Fletcher, Sue
Honeyman, Kaite
Fall, Abbie M.
Harding, Penny L.
Johnsen, Russell D.
Steinhaus, Joshua P.
Moulton, Hong M.
Iversen, Patrick L.
Wilton, Stephen D.
机构
[1] Univ Western Australia, Ctr Neuromuscular & Neurol Disorders, Perth, WA 6009, Australia
[2] Univ Western Australia, Royal Perth Hosp, Sch Med & Pharmacol, Cardiovasc Res Grp, Perth, WA 6009, Australia
[3] AVI BioPharma, Corvallis, OR USA
关键词
D O I
10.1038/sj.mt.6300245
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Duchenne and Becker muscular dystrophies are allelic disorders arising from mutations in the dystrophin gene. Duchenne muscular dystrophy is characterized by an absence of functional protein, whereas Becker muscular dystrophy, commonly caused by in-frame deletions, shows synthesis of partially functional protein. Anti-sense oligonucleotides can induce specific exon removal during processing of the dystrophin primary transcript, while maintaining or restoring the reading frame, and thereby overcome protein-truncating mutations. The mdx mouse has a non-sense mutation in exon 23 of the dystrophin gene that precludes functional dystrophin production, and this model has been used in the development of treatment strategies for dystrophinopathies. A phosphorodiamidate morpholino oligomer ( PMO) has previously been shown to exclude exon 23 from the dystrophin gene transcript and induce dystrophin expression in the mdx mouse, in vivo and in vitro. In this report, a cell-penetrating peptide ( CPP)- conjugated oligomer targeted to the mouse dystrophin exon 23 donor splice site was administered to mdx mice by intraperitoneal injection. We demonstrate dystrophin expression and near- normal muscle architecture in all muscles examined, except for cardiac muscle. The CPP greatly enhanced uptake of the PMO, resulting in widespread dystrophin expression.
引用
收藏
页码:1587 / 1592
页数:6
相关论文
共 50 条
  • [21] Extensive and Prolonged Restoration of Dystrophin Expression with Vivo-Morpholino-Mediated Multiple Exon Skipping in Dystrophic Dogs
    Yokota, Toshifumi
    Nakamura, Akinori
    Nagata, Tetsuya
    Saito, Takashi
    Kobayashi, Masanori
    Aoki, Yoshitsugu
    Echigoya, Yusuke
    Partridge, Terence
    Hoffman, Eric P.
    Takeda, Shin'ichi
    NUCLEIC ACID THERAPEUTICS, 2012, 22 (05) : 306 - 315
  • [22] Chemical and Mechanistic Toxicology Evaluation of Exon Skipping Phosphorodiamidate Morpholino Oligomers in mdx Mice
    Sazani, Peter
    Van Ness, Kirk P.
    Weller, Doreen L.
    Poage, Duane
    Nelson, Keith
    Shrewsbury, Stephen B.
    INTERNATIONAL JOURNAL OF TOXICOLOGY, 2011, 30 (03) : 322 - 333
  • [23] Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and Cmah-/-mdx mouse models of Duchenne muscular dystrophy
    Blain, Alison M.
    Greally, Elizabeth
    McClorey, Graham
    Manzano, Raquel
    Bette, Corinne A.
    Godfrey, Caroline
    O'Donovan, Liz
    Coursindel, Thibault
    Gait, Mike J.
    Wood, Matthew J.
    MacGowan, Guy A.
    Straub, Volker W.
    PLOS ONE, 2018, 13 (06):
  • [24] Tween 85-Modified Low Molecular Weight PEI Enhances Exon-Skipping of Antisense Morpholino Oligomer In Vitro and in mdx Mice
    Wang, Mingxing
    Wu, Bo
    Tucker, Jason D.
    Shah, Sapana N.
    Lu, Peijuan
    Bollinger, Lauren E.
    Lu, Qilong
    MOLECULAR THERAPY-NUCLEIC ACIDS, 2017, 9 : 120 - 131
  • [25] Efficient exon skipping of SGCG mutations mediated by phosphorodiamidate morpholino oligomers
    Wyatt, Eugene J.
    Demonbreun, Alexis R.
    Kim, Ellis Y.
    Puckelwartz, Megan J.
    Vo, Andy H.
    Dellefave-Castillo, Lisa M.
    Gao, Quan Q.
    Vainzof, Mariz
    Pavanello, Rita C. M.
    Zatz, Mayana
    McNally, Elizabeth M.
    JCI INSIGHT, 2018, 3 (09):
  • [26] Enhanced exon skipping in the 4CV dystrophic mouse model of muscular dystrophy through refined oligomer design
    Mitrpant, C.
    Fletcher, S.
    Pinniger, G.
    Johnsen, R.
    Kole, R.
    Wilton, S. D.
    NEUROMUSCULAR DISORDERS, 2012, 22 (9-10) : 858 - 858
  • [27] PMO-mediated dystrophin exon 23 skipping restores mitochondrial function in the mdx mouse heart
    Fletcher, S.
    Viola, H. M.
    Adams, A. M.
    Wilton, S. D.
    Hool, L. C.
    NEUROMUSCULAR DISORDERS, 2013, 23 (9-10) : 800 - 800
  • [28] Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse
    Mann, CJ
    Honeyman, K
    Cheng, AJ
    Ly, T
    Lloyd, F
    Fletcher, S
    Morgan, JE
    Partridge, TA
    Wilton, SD
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (01) : 42 - 47
  • [29] Dystrophic Pathology in the Intrinsic and Extrinsic Laryngeal Muscles in the mdx Mouse
    Smythe, Gayle M.
    JOURNAL OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2009, 38 (03): : 323 - 336
  • [30] In-frame Dystrophin Following Exon 51-Skipping Improves Muscle Pathology and Function in the Exon 52-Deficient mdx Mouse
    Aoki, Yoshitsugu
    Nakamura, Akinori
    Yokota, Toshifumi
    Saito, Takashi
    Okazawa, Hitoshi
    Nagata, Tetsuya
    Takeda, Shin'ichi
    MOLECULAR THERAPY, 2010, 18 (11) : 1995 - 2005